Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023

Blue Owl Buys $1bn In Assets Managed By Cowen

Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.

Finance Watch Public Company
• Source: Alamy

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public market debut. The proceeds will fund its development of genetic medicines to treat genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.

More from Financing

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By 

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Major Cash Injection Advances Augustine’s HDAC6 Hopes

 
• By 

The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.

More from Business

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 

A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?